Medreich

What Medreich does

Medreich Limited is a privately held, fully integrated pharmaceutical contract manufacturing and development organization (CMO & CDMO) headquartered in Bengaluru, India, with regional hubs in Feltham (UK) and Sydney (Australia). Founded circa 1975 and operating as a wholly-owned subsidiary of Japan's Meiji Holdings Co., Ltd. since 2015, the company delivers end-to-end pharmaceutical services spanning proof-of-concept, formulation development, analytical services, clinical manufacturing, commercial manufacturing, regulatory affairs, pharmacovigilance, and packaging design. Its technology platform focuses on oral solid dosage forms — tablets, capsules, dry powders, and dry powder injections — with advanced capabilities in modified-release, controlled-release, bi-layer/MUPS compression, twin-screw melting granulation, and bioequivalence study coordination.

The company operates seven state-of-the-art manufacturing facilities in Bengaluru, all approved by major regulatory bodies including UK MHRA, TGA Australia, Health Canada, PMDA Japan, MFDS South Korea, MCC South Africa, GCC, and PICS. Medreich holds approximately 130 active UK licenses, 70+ dossiers registered with TGA Australia and Medsafe NZ, and maintains in-house regulatory teams of 45+ experts supporting filings in CTD format across regulated and emerging markets.

Medreich generates revenue through contract manufacturing and development fees billed to pharmaceutical MNCs under multi-year, quote-based agreements. Its customer base includes GSK, Sanofi, Novartis, Sandoz, Johnson & Johnson, Abbott, Viatris, Pfizer, Mylan, Apotex, iNova, and Berlin Pharma, with products and services distributed across 54-60+ countries spanning the UK, Europe, Australia/New Zealand, Canada, Japan, Far East Asia, GCC, Africa, LATAM, and CIS. The company employs approximately 3,000-4,000 people across more than 20 nationalities and operates alongside a joint venture with Adcock Ingram South Africa established in 2007.

Name

Medreich

Legal name

Medreich Limited

Website

https://medreich.com

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Medreich is a Bengaluru-headquartered, India-based pharmaceutical CMO and CDMO serving global pharmaceutical MNCs with seven manufacturing facilities, formulation development, regulatory services, and commercial manufacturing across 60+ countries, owned by Japan's Meiji Holdings.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Contract pharmaceutical manufacturing
• Generic drug development
• Pharmaceutical formulation services
• Oral solid dosage manufacturing
• Regulatory filing services

Headquarters

HQ city

Feltham

HQ country

United Kingdom

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Contract Manufacturing (CMO): Provides pharmaceutical contract manufacturing services for various dosage forms to pharmaceutical companies including MNCs like GSK, Sanofi, Novartis, Sandoz, J&J, Abbott, Viatris. Manufacturing for global regulated markets with regulatory approvals from UK MHRA, TGA Australia, Health Canada, PMDA Japan, MFDS South Korea, MCC South Africa, GCC, PICS compliant.
2. Contract Development and Manufacturing (CDMO): Full-service CDMO providing formulation development, regulatory filings, and commercial manufacturing. Develops patent non-infringing and niche generics in differentiated dosage forms for global regulated markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Medreich is a pharmaceutical CMO and CDMO providing end-to-end contract manufacturing and development services for oral solid dosage forms including tablets, capsules, dry powders for suspensions, and dry powder for injections. The company develops patent non-infringing and niche generic formulations and operates seven state-of-the-art manufacturing facilities approved by UK MHRA, TGA Australia, Health Canada, PMDA Japan, MFDS South Korea, MCC South Africa, and GCC, supplying over 100+ generic formulations to pharmaceutical companies across 60+ countries.

Product overview

Medreich is a fully integrated pharmaceutical CMO & CDMO company offering end-to-end services from Idea Innovation to Commercial Manufacturing. The core offering spans Proof of Concept, Formulation Development, Analytical Services, Clinical Manufacturing, and Commercial Manufacturing services, supported by Regulatory Services, Pharmacovigilance, and Packaging Design & Development. The company maintains an extensive Product Portfolio of over 100+ generic pharmaceutical formulations across therapeutic categories including Antibacterials, Antihypertensives, Antidiabetics, Analgesics, Antidepressants, Antipsychotics, and more, available in various dosage forms. Medreich operates seven state-of-the-art manufacturing facilities and serves customers across 60+ countries in key markets including UK, Europe, Australia, Japan, and emerging markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Proof of Concept Services Novel drug delivery dosage form services using broad spectrum technology platforms for Proof of Concept studies, recognized for speed, precision, innovation with scalable feasibility using significantly smaller scale R&D batches. Targeted at pharmaceutical companies seeking early-stage feasibility assessment of novel drug delivery platforms.
• Formulation Development Services Extensive experience in timely development of oral solid dosage forms (OSD) including modified, controlled, and FDC immediate release formulations. Capabilities include direct powder blending, high shear granulation, fluid bed granulation, twin screw melting granulation, dry roller-compaction, bi-layer/MUPS compression, multi components capsule filling, and powder for reconstitution. Targeted at pharmaceutical companies requiring formulation development expertise.
• Analytical Services Analytical method development and validation services including API characterization, impurity profiling, solubility studies, dissolution studies, multi-media dissolution, diffusion studies, polymorphic studies, photo stability/stability studies as per ICH guidelines, microbiological testing, and analytical method validation. Targeted at pharmaceutical companies requiring analytical testing and method development.
• Clinical Manufacturing Services cGMP manufacturing for Bio Batch products including tablets and capsules, with batch sizes ranging from few thousand units to over a million units per batch. Includes bioavailability and bioequivalence study design, execution, and dossier compilation. Targeted at pharmaceutical companies requiring clinical supply manufacturing.
• Commercial Manufacturing Services Commercial-scale manufacturing across seven state-of-the-art manufacturing facilities producing various dosage forms including tablets, capsules, dry powders for suspensions, and dry powder for injections. Facilities include dedicated Beta-lactam and non-penicillin oral dosage formulation facilities. Targeted at pharmaceutical companies requiring commercial-scale supply.
• Regulatory Services A team of 45+ regulatory experts capable of undertaking regulatory filings in CTD format across regulated and emerging markets. Expertise in market authorization registration, CMC, preclinical, clinical, product information, labelling, and patient information leaflets preparation. Targeted at pharmaceutical companies requiring regulatory submission support.
• Pharmacovigilance Services Patient safety monitoring including adverse event case triage, detailed case entry and follow-up, narrative writing, quality reviews, medical review, and on-time global reporting to health authorities. Includes periodic safety update reports compilation, signal detection, and risk benefit analysis. Targeted at pharmaceutical companies requiring post-marketing safety surveillance.
• Packaging Design & Development Services Primary and secondary packaging development for various dosage forms including tablets, capsules, oral solutions/suspensions, syrup, injectables, sachets and ophthalmic preparations. Capabilities include blisters (PVC/PVDC/ACLAR, PP, Alu-Alu), strip, bottle with CRC & screw cap, and automated secondary packaging with anti-counterfeit features. Targeted at pharmaceutical companies requiring specialized packaging solutions.
• Pharmaceutical Formulations Product Portfolio Extensive portfolio of generic pharmaceutical formulations across therapeutic categories including Antibacterials, Antihypertensives, Antidiabetics, Analgesics, Antidepressants, Antipsychotics, and more. Available in multiple dosage forms (tablets, capsules, dry powders, injections) and strengths. Products include Amoxicillin, Bisoprolol, Metformin, Atorvastatin, and over 100+ other formulations. Targeted at pharmaceutical distributors and companies requiring finished generic products.
• Amiodarone Tablets Patient Alert Card Patient alert card program for Amiodarone 100mg and 200mg Tablets containing important safety information about potential serious side effects including lung damage, liver damage, heartbeat problems, and thyroid problems. Targeted at patients and healthcare providers dispensing or prescribing Amiodarone.

Quantifiable outcome

• 130 licenses in UK market with active utilization
• +3 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Adcock Ingram Pharma Private LimitedcoreStrategic or Co-development Partner · 1 January 2023100% subsidiary company of Medreich established in 2023 to expand manufacturing capacity. New State of the Art Manufacturing Facility in Bengaluru to manufacture Tablets, Effervescent Granules & Tablets and other dosage forms.
• Adcock Ingram (South Africa)coreStrategic or Co-development Partner · 1 January 2007In 2007, Medreich entered into a joint venture with Adcock Ingram South Africa establishing a State of the Art Manufacturing Facility in Bangalore to manufacture and supply solid dosage forms. The Joint Venture Company manufactures products for both the JV partners for various markets.
• FHC Farmaceutica PortugalminorChannel Partner/ Reseller/ DistributorMedreich joined hands with FHC Farmaceutica Portugal for distribution/partnership in European markets.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Emcure Pharmaceuticals: Indian-headquartered pharmaceutical company with generics, biosimilars, and contract manufacturing operations across OSD and sterile injectables, serving regulated and emerging markets. Comparable scale and customer overlap with Medreich.
• Aurobindo Pharma: Indian-headquartered generic pharmaceutical manufacturer with large-scale OSD manufacturing capacity, multi-jurisdictional regulatory approvals (USFDA, UK MHRA, etc.), and significant CMO/CDMO revenue. Directly comparable to Medreich in product category, customer base (global generic pharma), and business model.
• Alcami Corporation: US-headquartered CDMO offering formulation development, analytical services, and commercial manufacturing of oral solids and sterile products. Comparable in end-to-end CDMO service model and MNC customer base.
• Jubilant Pharmova: Indian integrated pharmaceuticals company with CDMO, generics, and API operations, including oral solid dosage manufacturing for regulated markets. Direct peer in the Indian CMO/CDMO landscape serving similar global customers.
• Piramal Pharma Solutions: Global CDMO offering integrated drug development and manufacturing services across oral solids, sterile injectables, and APIs. Highly comparable to Medreich's end-to-end CDMO service model and MNC customer base.
• Recipharm: European-headquartered CDMO offering formulation development and commercial manufacturing across oral solids, sterile, semi-solids, and APIs. Comparable in multi-jurisdictional approvals and MNC client base to Medreich's CMO/CDMO model.
• Cambrex: Global CDMO focused on small-molecule API and finished dosage form development and manufacturing. Comparable as a CDMO serving innovator and generic pharma across multiple regulated markets, with overlapping OSD capability.

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian-headquartered generic pharmaceutical manufacturer with global operations, OSD manufacturing, and contract manufacturing services. While primarily a branded/generic player, its CMO arm is a comparable peer for Medreich's generic OSD contract manufacturing offering.
• WuXi STA (WuXi AppTec): Global CDMO arm of WuXi AppTec providing end-to-end small-molecule development and manufacturing, including oral solids. Comparable end-to-end CDMO scope and MNC customer base, though significantly larger and broader in modality than Medreich.

Emerging players

• Syngene International: Indian contract research and manufacturing services organization (part of the Biocon Group) providing formulation development and manufacturing, including OSD, for global pharma clients. Comparable as an India-based CDMO serving MNCs, though with broader discovery and biologics exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medreich-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medreich